{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:02:53Z","timestamp":1780549373716,"version":"3.54.1"},"reference-count":31,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Purpose: Male breast cancer (maleBC) is an orphan disease. Aside from age, risk factors include genetic mutations and conditions like Klinefelter syndrome or other reasons of hypogonadism. Treatment is based on standards in women, but biological differences may exist, with maleBC exhibiting higher rates of hormone-receptor expression. Limiting data exists regarding the rate of low\/ultralow HER2 expression, a predictive biomarker for the antibody\u2013drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) in HER2-negative disease in women. Materials and Methods: We conducted a retrospective single-center analysis of clinicopathological features of maleBC at a tertiary cancer center. We identified a cohort of 57 maleBC patients, described demographic, pathological, prognostic and surgical and systemic treatment data and evaluated frequencies of low and ultralow HER2 expression. Results: The mean age was 64.3 (SE \u00b1 1.79) years; 94.7% (n = 54) of patients presented with early\/nonmetastatic breast cancer and 40.7% (22 of 54) of patients exhibited nodal involvement. Most patients (92.6%, 50 of 54 patients) had luminal disease and approximately one third of patients received chemotherapy. Endocrine therapy was administered in 87.7% (n = 50\/57) of cases. For 52 of the patients included, full receptor status data including HER2 IHC scoring and\/or histological specimens were available. IHC slides of tumor specimens from 24 patients with either historically reported \u201cHER2 negative\u201d or \u201cHER2 0\u201d expression were available for reassessment; 79.2% (n = 19 of 24) of these tumors exhibited either HER2-low or -ultralow expression. In the whole cohort, rates of HER2-low and -ultralow expression were 75.0% (39 of 52) and 5.8% (3 of 52 patients), respectively. The median follow-up was 7 years. Six deaths occurred in the total population (n = 57). The median event-free survival (EFS) was 8.39 years (95% CI 7.36\u201311.35). No statistically significant associations were observed between HER2 expression categories and clinicopathological variables including grade, ER status, nodal status, genetic variant status, age, Ki67 index, or overall survival events. Conclusions: In this cohort of maleBC patients, high rates of combined HER2-low and -ultralow expression were observed upon reassessment of tumors with historically negative HER2 status, shedding light on potential ADC eligibility in male breast cancer.<\/jats:p>","DOI":"10.3390\/life16060947","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T03:37:29Z","timestamp":1780544249000},"page":"947","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characterization of HER2 Expression Levels, Including HER2-Ultralow, in a Retrospective Male Breast Cancer Cohort"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8439-3312","authenticated-orcid":false,"given":"Maximilian","family":"Marhold","sequence":"first","affiliation":[{"name":"Division of Oncology, Department for Medicine I, Medical University of Vienna, W\u00e4hringer G\u00fcrtel 18-20, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Binder","sequence":"additional","affiliation":[{"name":"Institute for Pathology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Bago-Horvath","sequence":"additional","affiliation":[{"name":"Institute for Pathology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8429-3741","authenticated-orcid":false,"given":"Stefan","family":"Konrad","sequence":"additional","affiliation":[{"name":"Department of Radiooncology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8749-2501","authenticated-orcid":false,"given":"Daniela","family":"Kauer-Dorner","sequence":"additional","affiliation":[{"name":"Department of Radiooncology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert","family":"Bartsch","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department for Medicine I, Medical University of Vienna, W\u00e4hringer G\u00fcrtel 18-20, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Exner","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5484-6229","authenticated-orcid":false,"given":"Kerstin","family":"Wimmer","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"ref_1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1634\/theoncologist.10-7-471","article-title":"A review of the diagnosis and management of male breast cancer","volume":"10","author":"Giordano","year":"2005","journal-title":"Oncologist"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1245\/s10434-012-2479-z","article-title":"Gender differences in breast cancer: Analysis of 13,000 breast cancers in men from the National Cancer Data Base","volume":"19","author":"Greif","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2011.36.8902","article-title":"Incidence and outcome of male breast cancer: An international population-based study","volume":"29","author":"Miao","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/modpathol.2016.229","article-title":"Male breast cancer precursor lesions: Analysis of the EORTC 10085\/TBCRC\/BIG\/NABCG International Male Breast Cancer Program","volume":"30","author":"Doebar","year":"2017","journal-title":"Mod. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/annonc\/mdf166","article-title":"Recognizing features that are dissimilar in male and female breast cancer: Expression of p21Waf1 and p27Kip1 using an immunohistochemical assay","volume":"13","author":"Curigliano","year":"2002","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1158\/1078-0432.CCR-15-2840","article-title":"The Genomic Landscape of Male Breast Cancers","volume":"22","author":"Piscuoglio","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s10549-019-05429-z","article-title":"Germline investigation in male breast cancer of DNA repair genes by next-generation sequencing","volume":"178","author":"Scarpitta","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cncr.30337","article-title":"Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene","volume":"123","author":"Silvestri","year":"2017","journal-title":"Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.clbc.2014.02.008","article-title":"Outcome of male breast cancer: A matched single-institution series","volume":"14","author":"Iorfida","year":"2014","journal-title":"Clin. Breast Cancer"},{"key":"ref_11","first-page":"3027","article-title":"Aromatase inhibition in the human male reveals a hypothalamic site of estrogen feedback","volume":"85","author":"Hayes","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1056\/NEJMra1707939","article-title":"Breast Cancer in Men","volume":"378","author":"Giordano","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"LBA1000","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1000","article-title":"Trastuzumab deruxtecan (T-DXd) vs physician\u2019s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06)","volume":"42","author":"Curigliano","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Ignatov, A., Lempfer, S., Meszaros, J., and Eggemann, H. (2024). Prognostic Impact of HER2 Low Status in Male Breast Cancer: Prospective Cohort Analysis. Cancers, 16.","DOI":"10.3390\/cancers16193399"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2147\/BCTT.S450682","article-title":"HER2 Low Expression in Primary Male Breast Cancer","volume":"16","author":"Nobbe","year":"2024","journal-title":"Breast Cancer Targets Ther."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Silvestri, V., Valentini, V., Bucalo, A., Conti, G., Manzella, L., Turchetti, D., Russo, A., Capalbo, C., and Ottini, L. (2024). HER2-Low Expression in Male Breast Cancer: Results from a Multicenter Series in Italy. Cancers, 16.","DOI":"10.3390\/cancers16030548"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13000-025-01632-3","article-title":"Redefining therapeutic landscapes: Clinicopathological insights into low and ultra-low HER2 expression in male breast cancer","volume":"20","author":"Shang","year":"2025","journal-title":"Diagn. Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann. Surg."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update","volume":"41","author":"Wolff","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S1470-2045(21)00301-6","article-title":"Clinical and molecular characteristics of HER2-low-positive breast cancer: Pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials","volume":"22","author":"Denkert","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","volume":"7","author":"Schettini","year":"2021","journal-title":"npj Breast Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"100747","DOI":"10.1016\/j.esmoop.2022.100747","article-title":"Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer-results from an international, multicenter analysis coordinated by the AGMT Study Group","volume":"8","author":"Gampenrieder","year":"2023","journal-title":"ESMO Open"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41523-023-00533-2","article-title":"Estrogen\/HER2 receptor crosstalk in breast cancer: Combination therapies to improve outcomes for patients with hormone receptor-positive\/HER2-positive breast cancer","volume":"9","author":"Pegram","year":"2023","journal-title":"npj Breast Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ccell.2016.02.006","article-title":"Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4\/6 Inhibitors","volume":"29","author":"Goel","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: The phase 2 DAISY trial","volume":"29","author":"Mosele","year":"2023","journal-title":"Nat. Med."},{"key":"ref_28","first-page":"629","article-title":"Clinical characteristics of male patients with breast cancer in the Latino population","volume":"209","author":"Mohar","year":"2024","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e000880","DOI":"10.1136\/esmoopen-2020-000880","article-title":"Thirteen-year analyses of medical oncology outpatient day clinic data: A changing field","volume":"5","author":"Marhold","year":"2020","journal-title":"ESMO Open"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): Results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus Endocrine Therapy in Early Breast Cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N. Engl. J. Med."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/6\/947\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:16:10Z","timestamp":1780546570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/6\/947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["life16060947"],"URL":"https:\/\/doi.org\/10.3390\/life16060947","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]}}}